Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma, and included both lymphomas of B cells and T cells. We now know DLBCL is still heterogenous and some subtypes might benefit from specific therapies. The latest efforts to further optimize outcomes were described at the 2024 Debates in Hematology and Oncology Conference, sponsored by Emory University Winship Cancer Center, by lymphoma expert James O. Armitage, MD, FASCO. Dr. Armitage is the Joe Shapiro Professor of Medicine at the University of Nebraska and the Editor-in-Chief of The ASCO Post.
Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer
In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer.
Former President Biden Diagnosed With Metastatic Prostate Cancer
According to his office, Former President Joseph R. Biden Jr has been diagnosed with an “aggressive” type of prostate cancer that has spread to his bones. The New York Times reported that Mr. Biden’s cancer “is characterized by a Gleason score of 9 with metastasis to the bone.”
Gabapentin May Extend Survival in Patients With Glioblastoma
Investigators have found that the antiseizure/pain drug gabapentin may be associated with improved survival in patients with glioblastoma, according to a recent study published by Bernstock et al in Nature Communications.
Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus.
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
SPONSORED BY BREAST CANCER INDEX® BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-MakingMore Top Stories
How Could So Many Physicians Have Failed Me?
Oya Gilbert The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to ...
p53 Dysfunction in Myelodysplastic Syndromes
In a study reported in the Journal of Clinical Oncology, Zampini et al identified a proportion of patients with myelodysplastic syndromes who had nonmutational TP53 but p53 dysfunction, which was associated with poor disease outcomes. Study Details The study involved data from a cohort of 6,204...
Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research
Rakesh K. Jain, PhD, FAACR The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant...
Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD
Thomas B. Tomasi, Jr, MD, PhD Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s...
Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...
Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026
Keith T. Flaherty, MD, FAACR The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director...
Breast Cancer: Genome-Wide Study Identifies Two New Risk Genes in Black South African Women
Investigators have identified two genetic risk loci that may be associated with an increased risk of breast cancer for Black South African women, according to findings from a genome-wide association study published in Nature Communications. The two risk loci were between UNC13C and RAB27A on...
